AN2 Therapeutics, Inc.
NASDAQ Global SelectTotal Valuation
AN2 Therapeutics, Inc. carries a market capitalization of 132.36M, placing it among publicly traded companies globally.
| Market Cap | 132.36M |
| Enterprise Value | N/A |
Share Statistics
AN2 Therapeutics, Inc. currently has 36.31M shares outstanding.
| Shares Outstanding | 36.31M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 2.31 |
| P/TBV Ratio | 2.31 |
| P/FCF Ratio | -5.50 |
| P/OCF Ratio | -5.50 |
Financial Position
AN2 Therapeutics, Inc. maintains a current ratio of 14.32, meaning it holds 14.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 14.32 |
| Quick Ratio | 14.04 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -50.12 |
| Return on Assets (ROA) | -46.06 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
AN2 Therapeutics, Inc.'s stock has gained approximately 187.5082% over the past 52 weeks. The 50-day moving average sits at 5.25, while the 200-day moving average is 3.95.
| Beta (5Y) | N/A |
| 52-Week Price Change | 187.5082% |
| 50-Day Moving Average | 5.25 |
| 200-Day Moving Average | 3.95 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -38.81M, while operating income came in at -38.81M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -38.81M |
| Pretax Income | -36.28M |
| Net Income | -36.28M |
| EBITDA | -38.81M |
| EBIT | -38.81M |
| Earnings Per Share (EPS) | -1.04 |
Balance Sheet
Total book value stands at 75.92M, with working capital of 74.41M providing operational flexibility.
| Cash & Cash Equivalents | 78.39M |
| Total Debt | N/A |
| Net Debt | -44.32M |
| Equity (Book Value) | 75.92M |
| Book Value Per Share | 2.09 |
| Working Capital | 74.41M |
Cash Flow
AN2 Therapeutics, Inc. produced -30.68M in operating cash flow over the past twelve months.
| Operating Cash Flow | -30.68M |
| Capital Expenditures | N/A |
| Free Cash Flow | -30.68M |
| FCF Per Share | -0.88 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -22.12 |
| FCF Yield | -18.18 |
Scores
AN2 Therapeutics, Inc. posts an Altman Z-Score of 13.40, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 13.40 |